Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Dec 27, 2021; 13(12): 1550-1566
Published online Dec 27, 2021. doi: 10.4240/wjgs.v13.i12.1550
Neoadjuvant treatment strategies for hepatocellular carcinoma
Lei Xu, Lin Chen, Wei Zhang
Lei Xu, Lin Chen, Wei Zhang, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Author contributions: Xu L wrote the paper; Chen L revised the manuscript; Zhang W proposed the topic and finalized this review.
Supported by National Natural Science Foundation of China, No. 81860117.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Zhang, MD, Assistant Professor, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jie Fang Avenue, Wuhan 430030, Hubei Province, China. weizhangtjh@hust.edu.cn
Received: April 19, 2021
Peer-review started: April 19, 2021
First decision: June 13, 2021
Revised: June 27, 2021
Accepted: November 30, 2021
Article in press: November 30, 2021
Published online: December 27, 2021
Processing time: 248 Days and 11.7 Hours
Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. A considerable number of patients cannot receive radical therapy due to advanced HCC at the first diagnosis, leading to a poor prognosis. Neoadjuvant treatment enables more patients with HCC inside or outside the Milan criteria to receive surgical treatment, such as partial liver resection and liver transplantation. In this study, we reviewed the current status of neoadjuvant therapy in HCC.